New Haven, CTNCT03832361Now EnrollingIRB Ready

Endometrial Cancer Clinical Trial in New Haven, CT

Access cutting-edge endometrial cancer treatment through this phase 2 clinical trial at a research site in New Haven. Study-provided care at no cost to qualified participants.

Sponsored by Alessandro Santin

Quick Self-Assessment

See if you qualify for this New Haven location

Preparing your pre-screening questions…

Expert Care in New Haven

Access endometrial cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related endometrial cancer treatment provided free

Apply for This New Haven Location

Check if you qualify for this endometrial cancer clinical trial in New Haven, CT

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to New Haven

    Convenient for CT residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit New Haven site if eligible
  4. 4Begin participation

About This Endometrial Cancer Study in New Haven

The purpose of this study is to evaluate the activity and safety profile of mirvetuximab soravtansine (IMGN853) in patients with type II endometrial cancers that overexpress folate receptor alpha (FRα).

Sponsor: Alessandro Santin

Who Can Participate

Inclusion Criteria

Radiologically confirmed (ie, CT scan and/or MRI) persistent or recurrent endometrial cancer
Patients must have one of the following pathologically documented, definitively diagnosed tumor types: Uterine serous carcinoma (Pure or Mixed), Grade 2 or Grade 3 endometrial adenocarcinoma, Carcinosarcoma with high grade serous or Grade 2/3 endometrioid components, or clear cell carcinoma (Pure or Mixed).
Have measurable disease
FRα-positive tumor expression as defined in the protocol
Have at least one "target lesion" to be used to assess response as defined by RECIST v1.1
Patients must have received prior treatment with ≤ 3 prior lines of therapy for recurrent disease; hormonal agents are not considered a line of therapy; prior treatment with folate receptor-targeting investigational agents is not allowed
Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Time from prior therapy: Systemic anti-neoplastic therapy: five half-lives or four weeks, whichever is shorter; Radiotherapy: wide-field radiotherapy completed at least four weeks, or focal radiation completed at least two weeks, prior to starting study treatment
Patients must have resolution of toxic effect(s) of the most recent prior chemotherapy
Patients must have adequate hematologic, liver and kidney function as defined in the protocol
Women of child bearing potential (WCBP), must agree to use effective contraceptive methods during study treatment and for at least twelve weeks after the last dose of IMGN853
WCBP must have a negative pregnancy test within 4 days prior to the first dose of study treatment
At time of initial surgery, patient may have either been optimally or suboptimally debulked
Have signed the informed consent form, and willing to adhere to the study visit schedule and other protocol requirements
≥ 18 years of age

Exclusion Criteria

Active or chronic corneal disorder
Serious concurrent illness or clinically-relevant active infection as defined in the protocol
Clinically-significant cardiac disease such as recent myocardial infarction (≤ 6 months prior to day 1), unstable angina pectoris, uncontrolled congestive heart failure, uncontrolled hypertension, prior history of hypertensive crisis or hypertensive encephalopathy, uncontrolled cardiac arrhythmias, clinically-significant vascular disease, severe aortic stenosis, clinically significant peripheral vascular disease, or cardiac toxicity following prior chemotherapy
History of neurological conditions
History of hemorrhagic or ischemic stroke within the last 6 months
History of cirrhotic liver disease
Previous clinical diagnosis of non-infectious pneumonitis
Prior hypersensitivity to monoclonal antibodies
Women who are pregnant or breast feeding
Carcinomatous meningitis, untreated central nervous system (CNS) disease or symptomatic CNS metastasis
History or evidence of thrombotic or hemorrhagic disorders within 6 months before first study treatment
Required used of folate-containing supplements (e.g. folate deficiency)
Has a known additional malignancy that is progressing or required active treatment within 3 years of first dose of study treatment

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in New Haven?

Yes, this clinical trial (NCT03832361) has an active research site in New Haven, CT that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Endometrial Cancer Treatment Options in New Haven, CT

If you're searching for endometrial cancer treatment options in New Haven, CT, this clinical trial (NCT03832361) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our New Haven research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced endometrial cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all endometrial cancer clinical trials near you to find additional studies recruiting in your area.

More Endometrial Cancer Trials in New Haven, CT

See all endometrial cancer clinical trials recruiting in New Haven — not just this study.

Browse Endometrial Cancer Trials in New Haven →

Browse More Trials by Condition

Endometrial Cancer TrialsEssential Tremor TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in New Haven?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · New Haven, CT